Device Trial Radar · NCT06492746
Personal BP - CAI Study
Last checked: Nov 20, 2026Latest source record: Jul 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Jun 3, 2024
Primary completion
Jan 2027
Study completion Jan 2027
Sponsor
- Lead sponsor
- Becton, Dickinson and CompanyPublic (BDX)
- Sponsor type
- Industry
- First posted
- Jul 9, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A single-center, prospective, observational pilot of the Cerebral Adaptive Index for assessing personalized blood pressure targets
Conditions
- Blood Pressure
Interventions
HemoSphere Advanced Monitoring Platform with Acumen IQ sensor and Tissue Oximetry MonitoringDevice
The arterial line with Acumen IQ sensor and Foresight Elite sensor will be connected to the HemoSphere monitor with laptop displaying the CAI parameter.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To determine the magnitude and duration of CAITime frame: Duration of the procedure through 30 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Northwestern University Hospital
Evanston, Illinois · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.